Compare Amphastar Pharmaceuticals Inc (AMPH) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Otis Worldwide Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Otis Worldwide Corp trades at $73.33 (market cap $28.05B). The key difference: Otis Worldwide Corp is far larger — about 34× Amphastar Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.33% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OTIS | |
|---|---|---|
Market Cap | $826.08M | $28.05B |
Sector | Health | Industrials |
52-Week High | $30.81 | $101.07 |
52-Week Low | $16.87 | $69.34 |
Enterprise Value | $1.22B | $35.43B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Otis Worldwide trades at $73.09, up 1.51% today, amid a bearish technical signal despite neutral oscillators. The company reported mixed quarterly earnings, with Q1 2026 missing estimates, but maintains steady revenue growth and a 10.11% net income margin. Recent news highlights strategic modernization projects and a 5% dividend increase, while analyst consensus remains cautiously optimistic with a $94 price target.
The stock presents a value opportunity with a P/E of 19.44 below historical averages, but faces headwinds from China exposure and margin pressure. Upside potential exists if earnings rebound, though high debt and competitive risks warrant caution for investors seeking stable industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
